Studies that reported the usage of AR alone
| First author, year of publication, location of study . | Type of study . | No. of RSV cases . | LRI-final site of infection, no. (%) . | RSV deaths/LRI, no. (%) . | Treated at URI stage . | Progression, no. (%) . | Not treated at URI stage . | Progression, no. (%) . | Treated at LRI . | Deaths, no. (%) . | Not treated at LRI . | Deaths, no. (%) . | No. of patients on this regimen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schiffer (2009), WA7 | Retrospective | 44 | 12 (27) | 0 | 0 | 0 | 44 | 12 (27) | 6 | 0 | NA | NA | 6 AR |
| Boeckh (2007), WA24 | RCT | 14 | 3 (21) | 0 | 9 | 1 (11) | 5 | 2 (40) | 0 | 0 | 0 | 0 | 9 AR |
| Ebbert (2005), MN16 | Retrospective | 6 | 6 (100) | 4/6 (67) | 0 | 0 | 6 | 6 (100) | 4 | 2 (50) | 2 | 2 (100) | 4 AR |
| Martino (2005), TN6 | Prospective | 19 | 11 (58) | 2/11 (18) | NA | NA | NA | NA | NA | NA | NA | NA | 14 AR |
| Hassan (2003), United Kingdom54 | Retrospective | 6 | 2 (33) | 0/2 | 2 | 0 | 4 | 2 (50) | 2 | 0 | 0 | 0 | 4 AR |
| Ljungman (2001), Sweden10 | Prospective | 46 | 27 (59) | 8/27 (30) | 5 | 2 | 10 | 0 | 9 | 3 (33) | 2 | 1 (50) | AR |
| McColl (1998), United Kingdom55 | Retrospective | 5 | 2 (40) | 0/2 | 3 | 0 | 2 | 2 (100) | 2 | 0 | 0 | 0 | 5 AR |
| Bowden (1997), WA56 | Retrospective | 88 | 35 (40) | 24/35 (69) | 25 | 8 (32) | 0 | 0 | 8 | 7 (88) | 0 | 0 | 25 AR; 10 IR (reported in Table 3) |
| Harrington (1992), WA21 | Prospective | 31 | 18 (58) | 14/18 (78) | 0 | 0 | 31 | 18 (58) | 13 | 9 (69) | 5 | 5 (100) | 13 AR |
| Hertz (1989), MN22 | Prospective | 8 | 6 (75) | 4/6 (67) | 0 | 0 | 8 | 6 (75) | 6 | 4 (67) | 0 | 0 | 6 AR |
| Englund (1988), MN57 | Retrospective | 6 | 6 (100) | 3/6 (50) | 0 | 0 | 6 | 6 (100) | 6 | 3 (50) | 0 | 0 | 4 AR + 2 AR and IR |
| Total | 273 | 128/273 (47) | 59/128 (46) | 44 | 11/44 (25) | 116 | 54/116 (47) | 56 | 28/56 (50) | 9 | 8/9 (89) |
| First author, year of publication, location of study . | Type of study . | No. of RSV cases . | LRI-final site of infection, no. (%) . | RSV deaths/LRI, no. (%) . | Treated at URI stage . | Progression, no. (%) . | Not treated at URI stage . | Progression, no. (%) . | Treated at LRI . | Deaths, no. (%) . | Not treated at LRI . | Deaths, no. (%) . | No. of patients on this regimen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schiffer (2009), WA7 | Retrospective | 44 | 12 (27) | 0 | 0 | 0 | 44 | 12 (27) | 6 | 0 | NA | NA | 6 AR |
| Boeckh (2007), WA24 | RCT | 14 | 3 (21) | 0 | 9 | 1 (11) | 5 | 2 (40) | 0 | 0 | 0 | 0 | 9 AR |
| Ebbert (2005), MN16 | Retrospective | 6 | 6 (100) | 4/6 (67) | 0 | 0 | 6 | 6 (100) | 4 | 2 (50) | 2 | 2 (100) | 4 AR |
| Martino (2005), TN6 | Prospective | 19 | 11 (58) | 2/11 (18) | NA | NA | NA | NA | NA | NA | NA | NA | 14 AR |
| Hassan (2003), United Kingdom54 | Retrospective | 6 | 2 (33) | 0/2 | 2 | 0 | 4 | 2 (50) | 2 | 0 | 0 | 0 | 4 AR |
| Ljungman (2001), Sweden10 | Prospective | 46 | 27 (59) | 8/27 (30) | 5 | 2 | 10 | 0 | 9 | 3 (33) | 2 | 1 (50) | AR |
| McColl (1998), United Kingdom55 | Retrospective | 5 | 2 (40) | 0/2 | 3 | 0 | 2 | 2 (100) | 2 | 0 | 0 | 0 | 5 AR |
| Bowden (1997), WA56 | Retrospective | 88 | 35 (40) | 24/35 (69) | 25 | 8 (32) | 0 | 0 | 8 | 7 (88) | 0 | 0 | 25 AR; 10 IR (reported in Table 3) |
| Harrington (1992), WA21 | Prospective | 31 | 18 (58) | 14/18 (78) | 0 | 0 | 31 | 18 (58) | 13 | 9 (69) | 5 | 5 (100) | 13 AR |
| Hertz (1989), MN22 | Prospective | 8 | 6 (75) | 4/6 (67) | 0 | 0 | 8 | 6 (75) | 6 | 4 (67) | 0 | 0 | 6 AR |
| Englund (1988), MN57 | Retrospective | 6 | 6 (100) | 3/6 (50) | 0 | 0 | 6 | 6 (100) | 6 | 3 (50) | 0 | 0 | 4 AR + 2 AR and IR |
| Total | 273 | 128/273 (47) | 59/128 (46) | 44 | 11/44 (25) | 116 | 54/116 (47) | 56 | 28/56 (50) | 9 | 8/9 (89) |
RCT indicates randomized controlled studies; and NA, not available.